---
id: 160
title: Bacteroides fragilis Infections
category: organisms
subcategory: anaerobic_bacteria
tags: [Bacteroides, anaerobic, intra-abdominal, metronidazole, β-lactamase]
difficulty: easy
---

## Question

What infections does *B. fragilis* cause and how is it treated? Use the **"Intra-Abdominal, Polymicrobial, β-Lactamase+ → Metronidazole or Β-Lactam/Β-Lactamase Inhibitor"** framework.

## Answer

### ***Bacteroides fragilis* Overview:**

**Organism:**
- **Anaerobic, Gram-negative rod**
- **Normal colonic flora** (most common anaerobe in colon)
- **Produces β-lactamase** (resistant to penicillin, many cephalosporins)

### **Clinical Syndromes:**

**Intra-Abdominal Infections (Most Common):**
- **Perforated viscus:** Appendicitis, diverticulitis, perforated ulcer
- **Peritonitis, abscess** (liver, spleen, intra-abdominal)
- **Post-surgical infections** (GI, biliary surgery)
- **Almost always polymicrobial** (with Gram-negative rods like *E. coli*)

**Pelvic Infections:**
- **Tubo-ovarian abscess, endometritis**
- **Post-partum/post-abortion sepsis**

**Bacteremia:**
- **Usually from GI source** (intra-abdominal infection)
- **Can seed metastatic sites** (liver, brain abscesses)

**Brain Abscess:**
- **Often from hematogenous spread** (from GI or pulmonary source)
- **Polymicrobial** (with other anaerobes, streptococci)

**Aspiration Pneumonia/Lung Abscess:**
- **With other oral anaerobes** (often polymicrobial)

### **Treatment:**

**Preferred Agents:**

**Metronidazole:**
- **500mg IV/PO q8h**
- **Excellent activity** against *Bacteroides* and most anaerobes

**β-Lactam/β-Lactamase Inhibitor Combinations:**
- **Piperacillin-tazobactam 3.375g IV q6h** (or 4.5g q6-8h for severe infections)
- **Ampicillin-sulbactam 3g IV q6h**
- **Ticarcillin-clavulanate 3.1g IV q4-6h**

**Carbapenems:**
- **Meropenem 1g IV q8h**
- **Imipenem 500mg IV q6h**
- **Ertapenem 1g IV daily** (good for intra-abdominal, NOT Pseudomonas)

**Alternative:**
- **Moxifloxacin 400mg IV/PO daily** (has anaerobic activity)
- **Tigecycline 100mg IV × 1, then 50mg IV q12h**

**Intra-Abdominal Infections Require Combination:**
- **Cover Gram-negative aerobes + anaerobes**
- Examples:
  - **Ceftriaxone + metronidazole**
  - **Ciprofloxacin + metronidazole**
  - **Piperacillin-tazobactam** (monotherapy, covers both)

**Duration:** 4-7 days for source-controlled intra-abdominal infections, longer for abscess without drainage (weeks)

### **Source Control:**

**Surgical/Procedural Drainage ESSENTIAL:**
- **Abscess drainage** (percutaneous or surgical)
- **Repair perforated viscus**
- **Antibiotics alone insufficient** without source control

## Key Points

### **β-Lactamase Production:**
- **Resistant to:** Penicillin, ampicillin, many cephalosporins
- **Use:** Metronidazole OR β-lactam/β-lactamase inhibitor

### **Polymicrobial Infections:**
- *B. fragilis* **rarely causes infection alone**
- **Intra-abdominal:** Mixed with *E. coli*, *Klebsiella*, enterococci
- **Must cover aerobes + anaerobes**

### **Source Control Required:**
- **Antibiotics + drainage/surgery**
- **Cannot treat abscess with antibiotics alone** (especially >3-4 cm)

### **Metronidazole Gold Standard:**
- **Excellent anaerobic activity**
- **IV/PO equivalent bioavailability**
- **Resistance rare** (<5%)

### **Clinical Pearls:**
- **Most common anaerobe** in intra-abdominal infections
- **β-lactamase producer** → resistant to ampicillin, penicillin
- **Metronidazole** or **β-lactam/β-lactamase inhibitor** (pip-tazo, amp-sulbactam)
- **Always polymicrobial** (cover Gram-negatives + anaerobes)
- **Source control essential** (abscess drainage, surgical repair)

## Sources

- [IDSA: Intra-Abdominal Infection Guidelines 2024]

## Media

N/A
